2022
MP45-09 DISCRIMINATIVE SIGNIFICANCE OF PROSTATE BIOPSY DECIPHER SCORE TO PREDICT ADVERSE PATHOLOGY AND PATHOLOGICAL DISCORDANCE AT RADICAL PROSTATECTOMY
Khajir G, Kumar D, Rahman S, Leapman M, Levi A, Humphrey P, Sprenkle P. MP45-09 DISCRIMINATIVE SIGNIFICANCE OF PROSTATE BIOPSY DECIPHER SCORE TO PREDICT ADVERSE PATHOLOGY AND PATHOLOGICAL DISCORDANCE AT RADICAL PROSTATECTOMY. Journal Of Urology 2022, 207: e765. DOI: 10.1097/ju.0000000000002611.09.Peer-Reviewed Original ResearchAdverse pathologyDiscriminative significance
2018
Heterogeneity in early oncologic outcomes among men with NCCN intermediate-risk prostate cancer treated with radical prostatectomy.
Ghabili K, Nguyen K, Lu A, Hsiang W, Shuch B, Leapman M. Heterogeneity in early oncologic outcomes among men with NCCN intermediate-risk prostate cancer treated with radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 144-144. DOI: 10.1200/jco.2018.36.6_suppl.144.Peer-Reviewed Original ResearchIR prostate cancerAdjuvant radiation therapyNational Cancer DatabaseEarly oncologic outcomesClinical stageAdverse pathologyProstate cancerRadical prostatectomyRadiation therapyActive surveillanceIR patientsOncologic outcomesPathologic outcomesGS 3Intermediate-risk prostate cancerNational cancer registry dataIntermediate-risk featuresGS 4Cancer registry dataIR definitionLogistic regression analysisGleason upgradeLR patientsEarly outcomesIR group
2016
Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance.
Leapman M, Cowan J, Nguyen H, Cooperberg M, Carroll P. Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2016, 34: 124-124. DOI: 10.1200/jco.2016.34.2_suppl.124.Peer-Reviewed Original ResearchGenomic Prostate ScoreAdverse pathological findingsActive surveillanceProstate cancerRadical prostatectomyPathological findingsFavorable-risk prostate cancerIntermediate-risk prostate cancerIntermediate clinical riskNCCN risk classificationSerial prostate biopsyRisk prostate cancerSubsequent clinical outcomesTime of surgeryRT-PCR assaysPT3a diseaseDefinitive therapyIntermediate riskOncologic outcomesClinical outcomesAdverse pathologySerial biopsiesProstate biopsyMedian changeSerial changes
2015
MP42-12 CANCER OF THE PROSTATE RISK ASSESSMENT SCORE FOLLOWING BIOPSY GLEASON UPGRADE DURING PROSTATE CANCER ACTIVE SURVEILLANCE IS ASSOCIATED WITH ADVERSE PATHOLOGY AT PROSTATECTOMY
Leapman M, Ameli N, Chu C, Hussein A, Welty C, Cooperberg M, Carroll P. MP42-12 CANCER OF THE PROSTATE RISK ASSESSMENT SCORE FOLLOWING BIOPSY GLEASON UPGRADE DURING PROSTATE CANCER ACTIVE SURVEILLANCE IS ASSOCIATED WITH ADVERSE PATHOLOGY AT PROSTATECTOMY. Journal Of Urology 2015, 193: e513. DOI: 10.1016/j.juro.2015.02.1597.Peer-Reviewed Original ResearchAssociation of magnitude of cancer of the prostate risk assessment score change following biopsy gleason upgrade during prostate cancer active surveillance with adverse pathology at prostatectomy.
Leapman M, Ameli N, Chu C, Welty C, Hussein A, Cooperberg M, Carroll P. Association of magnitude of cancer of the prostate risk assessment score change following biopsy gleason upgrade during prostate cancer active surveillance with adverse pathology at prostatectomy. Journal Of Clinical Oncology 2015, 33: 76-76. DOI: 10.1200/jco.2015.33.7_suppl.76.Peer-Reviewed Original ResearchCAPRA scoreActive surveillanceProstate cancerAdverse pathologyBiopsy GleasonProstate cancer active surveillanceIntermediate-risk prostate cancerProstate Risk Assessment (CAPRA) scoreRisk categoriesMultivariate logistic regression modelAdverse surgical pathologyRisk prostate cancerAdverse pathological outcomesRisk assessment scoreLogistic regression modelsBiopsy upgradeGleason upgradeSurveillance biopsiesMedian ageRepeat biopsyInitial diagnosisSubsequent biopsyRadical prostatectomyMedian changeSurgical pathologyAssociation between a 17-gene genomic prostate score and multiparametric prostate MRI in men with low- and intermediate-risk prostate cancer (PCa).
Leapman M, Westphalen A, Ameli N, Lawrence H, Febbo P, Cooperberg M, Carroll P. Association between a 17-gene genomic prostate score and multiparametric prostate MRI in men with low- and intermediate-risk prostate cancer (PCa). Journal Of Clinical Oncology 2015, 33: 83-83. DOI: 10.1200/jco.2015.33.7_suppl.83.Peer-Reviewed Original ResearchGenomic Prostate ScoreIntermediate-risk prostate cancerLow-risk patientsRisk prostate cancerFavorable pathologyProstate cancerMean apparent diffusion coefficientRisk patientsApparent diffusion coefficientAdverse pathologyIntermediate-risk patientsSuspicious MRI findingsProstate MRISuspicion of malignancyMultiparametric prostate MRIFive-tier scaleRT-PCR assaysMRI findingsSingle institutionMulti-parametric prostate MRIProstate biopsyDominant lesionRisk groupsMR findingsMR score